NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 8,530 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 8,530 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $25.02, for a total value of $213,420.60. Following the sale, the insider now directly owns 11,812,033 shares in the company, valued at $295,537,065.66. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total value of $834,486.84.

NewAmsterdam Pharma Stock Down 4.0 %

Shares of NewAmsterdam Pharma stock opened at $23.68 on Wednesday. The company has a fifty day moving average price of $18.82 and a 200 day moving average price of $18.61. NewAmsterdam Pharma has a twelve month low of $8.90 and a twelve month high of $26.35.

Analysts Set New Price Targets

Several research analysts recently issued reports on NAMS shares. Royal Bank of Canada restated an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Piper Sandler restated an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, November 7th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $33.80.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. boosted its position in NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after purchasing an additional 628,251 shares during the period. Janus Henderson Group PLC boosted its position in NewAmsterdam Pharma by 51.1% during the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock worth $25,607,000 after purchasing an additional 520,772 shares during the period. Millennium Management LLC boosted its position in NewAmsterdam Pharma by 23.0% in the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after buying an additional 217,902 shares during the last quarter. Jennison Associates LLC boosted its position in NewAmsterdam Pharma by 8.9% in the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after buying an additional 83,115 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C boosted its position in NewAmsterdam Pharma by 30.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock valued at $16,698,000 after buying an additional 202,250 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.